


Highlights of This Issue 1

SPECIAL FEATURES

CCR Translations

- 3** Right-Sizing Adjuvant and Neoadjuvant Clinical Trials in Breast Cancer
Donald A. Berry
See related article, p. 26
- 6** Is It Better to Be Rich or Relaxed? Sociobiology Meets Bone Marrow Transplant
Lucie M. Turcotte and Michael R. Verneris
See related article, p. 69

CCR New Strategies

- 9** New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy
 Uwe Haberkorn, Matthias Eder, Klaus Kopka, John W. Babich, and Michael Eisenhut

Molecular Pathways

- 16** Molecular Pathways: IDH2 Mutations—Co-opting Cellular Metabolism for Malignant Transformation
Eytan M. Stein

Review

- 20** From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy
Liufu Deng, Hua Liang, Sherry Fu, Ralph R. Weichselbaum, and Yang-Xin Fu

CANCER THERAPY: CLINICAL

- 26** Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer
Christos Hatzis, W. Fraser Symmans, Ya Zhang, Rebekah E. Gould, Stacy L. Moulder, Kelly K. Hunt, Maysa Abu-Khalaf, Erin W. Hofstatter, Donald Lannin, Anees B. Chagpar, and Lajos Pusztai
See related commentary, p. 3

- 34** Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

Jatin J. Shah, Andrzej J. Jakubowiak, Owen A. O'Connor, Robert Z. Orlowski, R. Donald Harvey, Mitchell R. Smith, Daniel Lebovic, Catherine Diefenbach, Kevin Kelly, Zhaowei Hua, Allison J. Berger, George Mulligan, Hélène M. Faessel, Stephen Tirrell, Bruce J. Dezube, and Sagar Lonial

- 44** A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

Martin Schlumberger, Barbara Jarzab, Maria E. Cabanillas, Bruce Robinson, Furio Pacini, Douglas W. Ball, Judith McCaffrey, Kate Newbold, Roger Allison, Renato G. Martins, Lisa F. Licitra, Manisha H. Shah, Donald Bodenner, Rossella Elisei, Lynn Burmeister, Yasuhiro Funahashi, Min Ren, James P. O'Brien, and Steven I. Sherman

- 54** An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy

Masanori Noguchi, Kazumasa Matsumoto, Hirotsugu Uemura, Gaku Arai, Masatoshi Eto, Seiji Naito, Chikara Ohyama, Yasutomo Nasu, Masatoshi Tanaka, Fukuko Moriya, Shigetaka Suekane, Satoko Matsueda, Nobukazu Komatsu, Tetsuro Sasada, Akira Yamada, Tatsuyuki Kakuma, and Kyogo Itoh

- 61** A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

Andrew H. Ko, Tanius Bekaii-Saab, Jessica Van Ziffle, Olga M. Mirzoeva, Nancy M. Joseph, AmirAli Talasaz, Peter Kuhn, Margaret A. Tempero, Eric A. Collisson, R. Kate Kelley, Alan P. Venook, Elizabeth Dito, Anna Ong, Sharvina Ziyeh, Ryan Courtin, Regina Linskaya, Sanaa Tahiri, and W. Michael Korn

PERSONALIZED MEDICINE AND IMAGING

- 69** Low Socioeconomic Status, Adverse Gene Expression Profiles, and Clinical Outcomes in Hematopoietic Stem Cell Transplant Recipients
Jennifer M. Knight, J. Douglas Rizzo, Brent R. Logan, Tao Wang, Jesusa M.G. Arevalo, Jeffrey Ma, and Steve W. Cole
See related commentary, p. 6



Table of Contents

- 79** Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms
Mohid S. Khan, Amy A. Kirkwood, Theodora Tsigani, Helen Lowe, Robert Goldstein, John A. Hartley, Martyn E. Caplin, and Tim Meyer

CANCER THERAPY: PRECLINICAL

- 86** Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
Martin Skarzynski, Carsten U. Niemann, Yuh Shan Lee, Sabrina Martyr, Irina Maric, Dalia Salem, Maryalice Stetler-Stevenson, Gerald E. Marti, Katherine R. Calvo, Constance Yuan, Janet Valdez, Susan Soto, Mohammed Z.H. Farooqui, Sarah E.M. Herman, and Adrian Wiestner
- 96** Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors
Lukas J.A.C. Hawinkels, Amaya Garcia de Vinuesa, Madelon Paauwe, Marianna Kruithof-de Julio, Eliza Wiercinska, Evangelia Pardali, Laura Mezzanotte, Stijn Keereweer, Tanya M. Braumuller, Renier C. Heijkants, Jos Jonkers, Clemens W. Löwik, Marie-José Goumans, Timo L. ten Hagen, and Peter ten Dijke
- 107** Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer
Andreas Varkaris, Paul G. Corn, Nila U. Parikh, Eleni Efstathiou, Jian H. Song, Yu-Chen Lee, Ana Aparicio, Anh G. Hoang, Sanchaika Gaur, Lynnelle Thorpe, Sankar N. Maity, Menashe Bar Eli, Bogdan A. Czerniak, Yiping Shao, Mian Alauddin, Sue-Hwa Lin, Christopher J. Logothetis, and Gary E. Gallick
- 122** Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers *In Vitro* and *In Vivo*
Zhen Tao, Justin M. Le Blanc, Chenguang Wang, Tingting Zhan, Hongqing Zhuang, Ping Wang, Zhiyong Yuan, and Bo Lu
- 134** Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances
Gema Perez-Chacon, Carolina Martinez-Laperche, Nerea Rebolleda, Beatriz Somovilla-Crespo, Cecilia Muñoz-Calleja, Ismael Buño, and Juan M. Zapata

BIOLOGY OF HUMAN TUMORS

- 146** Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Siker Kimbung, Ida Johansson, Anna Danielsson, Srinivas Veerla, Suzanne Egyhazi Brage, Marianne Frostvik Stolt, Lambert Skoog, Lena Carlsson, Zakaria Einbeigi, Elisabet Lidbrink, Barbro Linderholm, Niklas Loman, Per-Olof Malmström, Martin Söderberg, Thomas M. Walz, Märten Fernö, Thomas Hatschek, and Ingrid Hedenfalk in collaboration with the TEX study group
- 158** CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
Bruno G. Leclerc, Roxanne Charlebois, Guillaume Chouinard, Bertrand Allard, Sandra Pommey, Fred Saad, and John Stagg
- 167** Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia
Anna Vardi, Andreas Agathangelidis, Evangelia Stalika, Maria Karypidou, Alexandra Siorenta, Achilles Anagnostopoulos, Richard Rosenquist, Anastasia Hadzidimitriou, Paolo Chia, Lesley-Ann Sutton, and Kostas Stamatopoulos
- 175** PKC α Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance
Kinnari Pandya, Debra Wyatt, Brian Gallagher, Deep Shah, Andrew Baker, Jeffrey Bloodworth, Andrei Zlobin, Antonio Pannuti, Andrew Green, Ian O. Ellis, Aleksandra Filipovic, Jason Sagert, Ajay Rana, Kathy S. Albain, Lucio Miele, Mitchell F. Denning, and Clodia Osipo
- 187** ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy
Zheng Chen, Albert E. Teo, and Nami McCarty
- 200** Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS)
Florian Posch, Johannes Thaler, Gerhard-Johann Zlabinger, Oliver Königsbrügge, Silvia Koder, Christoph Zielinski, Ingrid Pabinger, and Cihan Ay

Table of Contents

- 207** Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma
Irena Misiewicz-Krzeminska, María E. Sarasquete, Carolina Vicente-Dueñas, Patryk Krzeminski, Katarzyna Wiktorska, Luis Antonio Corchete, Dalia Quwaider, Elizabetha A. Rojas, Rocío Corral, Ana A. Martín, Fernando Escalante, Abelardo Báñez, Juan Luis García, Isidro Sánchez-García, Ramón García-Sanz, Jesús F. San Miguel, and Norma C. Gutiérrez
- 218**  Prognostic and Chemotherapy Predictive Value of Gene-Expression Phenotypes in Primary Lung Adenocarcinoma
Markus Ringnér, Göran Jönsson, and Johan Staaf
- 230** EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
Philip D. Dunne, Sonali Dasgupta, Jaine K. Blayney, Darragh G. McArt, Keara L. Redmond, Jessica-Anne Weir, Conor A. Bradley, Takehiko Sasazuki, Senji Shirasawa, Tingting Wang, Supriya Srivastava, Chee Wee Ong, Ken Arthur, Manuel Salto-Tellez, Richard H. Wilson, Patrick G. Johnston, and Sandra Van Schaeybroeck
- 243** Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening
Anssi Auvinen, Sue M. Moss, Teuvo L.J. Tammela, Kimmo Taari, Monique J. Roobol, Fritz H. Schröder, Chris H. Bangma, Sigrid Carlsson, Gunnar Aus, Marco Zappa, Donella Puliti, Louis J. Denis, Vera Nelen, Maciej Kwiatkowski, Marco Randazzo, Alvaro Paez, Marcos Lujan, and Jonas Hugosson
- 250** Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor
Anna Karpathakis, Harpreet Dibra, Chistodoulos Pipinikas, Andrew Feber, Tiffany Morris, Joshua Francis, Dahmane Oukrif, Dalvinder Mandair, Marinos Pericleous, Mullan Mohmaduvesh, Stefano Serra, Olagunju Ogunbiyi, Marco Novelli, TuVinh Luong, Sylvia L. Asa, Matthew Kulke, Christos Toumpanakis, Tim Meyer, Martyn Caplin, Matthew Meyerson, Stephan Beck, and Christina Thirlwell
- 259** The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten, Sheryl Elkin, Elisa Arthur, Brett N. Tomson, Jennifer Carter, and Razelle Kurzrock
- LETTERS TO THE EDITOR**
- 268** Neoadjuvant as Future for Drug Development in Breast Cancer—Letter
Marc Buyse, Tomasz Burzykowski, and Everardo D. Saad
- 269** Neoadjuvant as Future for Drug Development in Breast Cancer—Response
Angela DeMichele, Douglas Yee, Melissa Paoloni, Don Berry, and Laura J. Esserman, on behalf of the I-SPY2 Investigators
- RETRACTION**
- 270** Retraction: Suppression of *N*-Methyl-*N*-nitrosourea/Testosterone-Induced Rat Prostate Cancer Growth by Celecoxib: Effects on Cyclooxygenase-2, Cell Cycle Regulation, and Apoptosis Mechanism(s)

 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>


For more information please visit www.aacrjournals.org



Table of Contents

ABOUT THE COVER

The cover shows a section from a patient-derived xenograft of prostate cancer grown in mice treated with the MET/VEGFR-2 inhibitor, cabozantinib. Immunohistochemical staining shows an islet of viable tumor cells surrounding a VEGFR-2-negative blood vessel, with apoptotic cells surrounding the islet. For details, see the article by Varkaris and colleagues on page 107 of this issue.



Clinical Cancer Research

22 (1)

Clin Cancer Res 2016;22:1-270.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/22/1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/22/1>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.